On May 13, 2023, Suzhou Puhe Biopharma Co., Ltd. successfully held a national researchers Meeting in Beijing on the Phase III clinical study of YK-029A Tablet, the first independently developed Class I new drug, compared with platinum-containing dual drug chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC with EGFR Ex20ins mutation. Nearly a hundred researchers from 60 Research Centers of China attended the meeting together. This clinical study was led by Professor Wang Jie from the Cancer Hospital of the Chinese Academy of Medical Sciences, with Puhe Biopharma as the Sponsor and Triapex as the Supporter.。